Celcuity Publishes Presentation on Updated VIKTORIA-1 Study 2 Breast Cancer Results

Bitget2026/10/24 08:21

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Celcuity published updated VIKTORIA-1 Study 2 results in PIK3CA-mutant, HR-positive/HER2-negative advanced breast cancer.
Gedatolisib with fulvestrant and palbociclib significantly improved progression-free survival versus alpelisib with fulvestrant, reaching a median 11.1 months (hazard ratio: 0.50).
Without palbociclib, gedatolisib with fulvestrant significantly improved progression-free survival versus the same comparator, reaching a median 11.3 months (hazard ratio: 0.51).
Adverse events associated with gedatolisib-based treatment were mainly grade 1 or 2.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Celcuity Inc. published the original content used to generate this news brief on October 24, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Celcuity Publishes Presentation on Updated VIKTORIA-1 Study 2 Breast Cancer Results

You may also like

Crypto prices